Ten Capital Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Ten Capital Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30	Closed	-$9.45K	–	532
2023 Q1	$9.45K	Hold	30	–	–	﹤0.01%	371
2022 Q4	$8.66K	Hold	30	–	–	﹤0.01%	325
2022 Q3	$9K	Hold	30	–	–	﹤0.01%	324
2022 Q2	$8K	Hold	30	–	–	﹤0.01%	290
2022 Q1	$8K	Hold	30	–	–	﹤0.01%	325
2021 Q4	$7K	Buy	+30	New	+$5.83K	﹤0.01%	348

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ten Capital Wealth Advisors's VRTX Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 30 shares — an estimated $9.45K sold.

Ten Capital Wealth Advisors first reported a position in VRTX in Q4 2021 and held it in 6 quarters. The position peaked at $9.45K in Q1 2023. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

Ten Capital Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ten Capital Wealth Advisors sold 30 Vertex Pharmaceuticals shares in Q2 2023, an estimated $9.45K.
Ten Capital Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Ten Capital Wealth Advisors's Vertex Pharmaceuticals position peaked at $9.45K in Q1 2023.
1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.